10-K/A: International Isotopes Inc. Files Amendment to 2024 Annual Report

International Isotopes Inc. filed an amendment to its 2024 annual report to include previously omitted information regarding directors, executive compensation, security ownership, related transactions, and principal accountant fees.

Summary

• International Isotopes Inc. is filing Amendment No. 1 on Form 10-K/A to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• The amendment includes information required by Items 10 through 14 of Part III of Form 10-K, which was previously omitted.
• The company's Board of Directors consists of four members: Christopher Grosso, Dr. Robert Atcher, Steve T. Laflin, and Shahe Bagerdjian.
• Shahe Bagerdjian serves as the President and Chief Executive Officer, and W. Matthew Cox serves as the Chief Financial Officer and Secretary.
• As of April 28, 2025, the number of outstanding shares of the company's common stock was 526,266,791.
• The aggregate market value of voting and non-voting common equity held by non-affiliates as of June 30, 2024, was approximately $6 million.
• Kennerman Associates Inc. beneficially owns 42.4% of the company's common stock, while John M. McCormack and related parties beneficially own 20.7%.
• The company maintains two equity compensation plans: the Amended and Restated Employee Stock Purchase Plan (ESPP) and the 2015 Plan.
• The company had $31,337,500 in outstanding options, warrants and rights with a weighted-average exercise price of $0.05.
• The company had $21,009,925 in securities remaining available for future issuance under equity compensation plans.
• The company had related person transactions including a 2018 Promissory Note with accrued interest of $48,170 and a 2019 Promissory Note with accrued interest of $199,131 as of December 31, 2024.
• Haynie & Company served as the independent auditors, with fees of $122,784 for audit services in 2024.

Sentiment

Score: 6

Explanation: The document is primarily factual and descriptive, with a neutral tone. The presence of related party transactions and delinquent filings slightly lowers the sentiment.

Positives

• The company has an Audit Committee comprised of independent directors.
• The company has adopted a Code of Ethics for its principal executive officer, principal financial officer, principal accounting officer or controller, and directors.
• The company has insider trading policies and procedures in place.
• The company's equity compensation plans were previously approved by shareholders.

Negatives

• The company has related person transactions, including promissory notes with executive officers and major shareholders.
• The company's aggregate market value of voting and non-voting common equity held by non-affiliates as of June 30, 2024, was approximately $6 million.
• The company had delinquent Section 16(a) reports for Shahe Bagerdjian and Chris Grosso.

Risks

• The company's reliance on key personnel, such as John Miller, for regulatory compliance and licensing.
• Potential risks associated with related person transactions.
• The company's dependence on shareholder approval for equity compensation plans.

Future Outlook

No specific forward-looking statements or guidance are provided in this document.

Industry Context

This document provides information about the company's governance, executive compensation, and ownership structure, which are standard disclosures for publicly traded companies in the nuclear medicine and isotope industry.

Comparison to Industry Standards

• Executive compensation packages appear to be in line with industry standards for smaller reporting companies.
• The board composition and committee structure are typical for companies listed on Nasdaq.
• The related party transactions are disclosed as required by SEC regulations, but their presence may raise concerns about potential conflicts of interest.

Related Party Transactions

• In April 2018, the company borrowed $120,000 from its then Chief Executive Officer and Chairman of the Board pursuant to a promissory note (the 2018 Promissory Note).
• In December 2019, the company entered into a promissory note agreement with its then Chief Executive Officer, Chairman of the Board, former Chairman of the Board, and one of its major shareholders (the 2019 Promissory Note).

Stakeholder Impact

• Shareholders are provided with updated information on executive compensation, security ownership, and related party transactions.
• Employees are affected by the equity compensation plans and executive employment agreements.
• The company's relationships with its auditors and legal counsel are disclosed.

Key Dates

Keywords

International Isotopes Inc., Annual Report, Amendment, Executive Compensation, Security Ownership, Related Transactions, Audit Fees, Directors, Officers, Corporate Governance